A comprehensive study of multiple FDA-approved and promising MPNST therapies revealed that low-dose MEK inhibitors demonstrate the strongest synergy and efficacy when combined with other agents. The gene discussed is MAP2K7; the disease is malignant peripheral nerve sheath tumor.